

Aventis Pharma Deutschland GmbH

DEAV2002/0069

Abstract**Crystals of insulin analogs and a process for their preparation**

The invention relates to crystals of an insulin analog in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring neutral or acidic amino acid residue, where phenylalanine (Phe) in position B1 of the B chain can optionally be absent, the crystals being present in the space group R3 (No. 146) with the cell axes A = 81.5 Å ± 1Å and C = 33.3 Å ± 1 Å, their preparation and use, and a pharmaceutical composition comprising these crystals.